Background The extent of cross-protection is a key element in the choice of human
papillomavirus (HPV) vaccine to use in vaccination programmes. We compared the cross …

Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-
adolescent females has been introduced in most developed countries, supported by …

Background Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now
licensed in several countries. Furthermore, clinical trials examining the efficacy of a …

Prophylactic human papillomavirus (HPV) vaccines are administered in vaccination
programs, targeted at young adolescent girls before sexual exposure, and in catch-up …

Background Human papillomavirus (HPV) vaccination offers potential for primary prevention
of HPV-related pre-cancers and cancers as demonstrated in clinical trials. Mathematical …

Cervical cancer is the third most common cancer in women worldwide and often affects
women under 40 years of age with young families. Vaccination against HPV is a major …

Background Health economic evaluations of interventions in infectious disease are
commonly based on the predictions of ordinary differential equation (ODE) systems or …

Cervical cancer is the second leading cause of cancer deaths among women in the world
and more than 85% of cervical cancer cases occur in women living in developing countries …

Cervical cancer is the third most common cancer in women worldwide and often affects
women under 40 years with young families. Vaccination against the human papillomavirus …

Addition of the HPV vaccine to available cytological screening has been proposed to
increase HPV-related cancer prevention. A comprehensive review on this combined strategy …